HIGHLIGHTS
- who: March and colleagues from the Ludwig Maximilian University of Munich, Germany have published the article: Identi fi cation of immune related molecular subtypes and prognosis model for predicting prognosis, drug resistance in cervical squamous cell carcinoma, in the Journal: (JOURNAL)
- what: Currently, the most comprehensive immunotherapy is immune checkpoint inhibitor, whose representative drug is programmed death protein 1(PD-1) inhibitor (Pembrolizumab), which has been proved effective in a variety of cancers, but the overall objective effective rate is only 20%- 30% (Iwai et_al, 2017).
- how: The differences of TME gene signatures . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.